Dual acting SNRI-NMDA antagonists for the treatment of genitourinary disorders

• US 20050282859A1
• Filed: 06/03/2005
• Published: 12/22/2005
• Est. Priority Date: 06/04/2004
• Status: Abandoned Application

• Current Assignee: Edusa Pharmaceuticals, Inc.
• Original Assignee: Edusa Pharmaceuticals, Inc.
• Inventors: Thor, Karl Bruce
• Application Number:
  US11/145,022
• Publication Number:
  US 20050282859A1
• Time in Patent Office: Days
• US Class Current: 514/317
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/138 Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/403 condensed with carbocyclic rings, e.g. carbazole
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Discolsed herein are compositions and methods for treatment of genitourinary disorders (e.g., urge incontinence). The compositions may generally include a dual-acting SNRI-NMDA antagonist (e.g., bicifadine and/or milnacipran). Alternatively, the compositions may generally include an SNRI and an NMDA antagonist.

Claims

1. A method of treating a genitourinary disorder in a subject in need of treatment, comprising administering to the subject a therapeutically effective amount of a dual acting SNRI-NMDA antagonist, such that the genitourinary disorder is treated:

2. The method of claim 1, wherein the dual acting SNRI-NMDA antagonist comprises:

a first amount of an SNRI; and

a second amount of an NMDA antagonist.

3. The method of claim 2, wherein the first amount is a therapeutically effective amount and the second amount is a therapeutically effective amount.

4. The method of claim 2, wherein the first amount and the second amount together form a therapeutically effective amount.

5. The method of claim 1, wherein the dual acting SNRI-NMDA antagonist comprises:

one agent having both SNRI activity and NMDA antagonist activity.

6. The method of claim 1, wherein the dual acting SNRI-NMDA antagonist is a compound of Formula I:

7. The method of claim 6, wherein:

R₁, R₂, R₂′

, R₃ and R₃′

are each independently selected from the group consisting of H, alkyl, aryl, alkoxy, alkoxyalkyl, cycloalkyl, amino, nitro, acetamido, hydroxyl, trifluoromethyl and halogen;

R₄, R₄′

, R₅, R R₆′

, R₈, and R₈′

are each independently selected from the group consisting of H, alkyl, aryl, alkoxy, alkoxyalkyl, cycloalkyl, halogen and hydroxyl;

or

R₆ and R₆′

together form ═

O, ═

S, ═

NH or ═

CH₂; and

/or

R₈ and R₈′

together form ═

O, ═

S, ═

NH or ═

CH₂; and

R₇ is selected from the group consisting of H, alkyl, aryl, alkoxy, alkoxyalkyl, cycloalkyl, acyl, carboxyl and carbonyl.

8. The method of claim 6, wherein:

R₁, R₂, R₂′

, R₃ and R₃′

are each independently selected from the group consisting of H, C₁-C₆ alkyl, C₁-C₆ alkoxy and halogen;

R₄, R₄′

, R₅, R₆, R₆′

, R₈, and R₈′

are each independently selected from the group consisting of H, C₁-C₆ alkyl, halogen and hydroxyl;

or

R₆ and R₆′

together form ═

O; and

/or

R₈ and R₈′

together form ═

O; and

R₇ is selected from the group consisting of H or C₁-C₆ alkyl optionally substituted with aryl or substituted aryl.

9. The method of claim 6, wherein at least one of R₁, R₂, R₂′

, R₃ and R₃′

is other than hydrogen.

10. The method of claim 6, wherein R₁ and R₂′

, are not both chlorine when R₂, R₃, R₃′

, R₄, R₄′

, R₅, R₆, R₆′

, R₇, R₈, and R₈′

are hydrogen.

11. The method of claim 6, wherein the dual acting SNRI-NMDA antagonist is a single enantiomer.

12. The method of claim 1, wherein the dual acting SNRI-NMDA antagonist is at least one member selected from the group consisting of compounds represented by the following structural formulas:

13. The method of claim 1, wherein the dual acting SNRI-NMDA antagonist is a compound of Formula II:

14. The method of claim 13, wherein X is O.

15. The method of claim 13, wherein Y is selected from the group consisting of O and NF₄′

.

16. The method of claim 13, wherein n and p are each 1.

17. The method of claim 13, wherein R₁, R₂, R₂′

, R₃, R₃′

, are each independently selected from the group consisting of H, alkyl, alkoxy, amino, nitro, halogen, or hydroxyl.

18. The method of claim 13, wherein R₄ and R₄′

are each independently selected from the group consisting of H, alkyl, aryl, aralkyl, or optionally R₄ and R₄′

together form a heterocyclic ring.

19. The method of claim 13, wherein R₇”

is selected from the group consisting of NR₈R₈′

or OR₈.

20. The method of claim 13, wherein R₈, and R₈′

are each independently selected from the group consisting of H, alkyl, or optionally R₈ and R₈′

together form a heterocyclic ring.

21. The method of claim 13, wherein R₅, R₅′

, R₆, R₇, and R₇′

are each independently selected from the group consisting of H, alkyl, or aryl.

22. The method of claim 13, wherein n and p are each independently 0 and R₄ and R₇ form a direct bond between Y and Z.

23. The method of claim 13, wherein R₁, R₂, R₂′

, R₃ and R₃′

are H;

X is O;

Y is O or NR₄′

;

n and p are each 1;

R₇″

is selected from the group consisting of H, NR₈R₈′

or OR₈; and

R₄, R₄′

, R₅, R₅′

, R₆, R₇, R₇′

, R₈, and R₈′

are each independently selected from the group consisting of H or C₁-C₆ alkyl.

24. The method of claim 13, wherein R₁, R₂, R₂′

, R₃ and R₃′

are H;

X is O;

Y is selected from the group consisting of O or NR₄′

;

n and p are each 0 and R₄ and R₇ form a direct bond between Y and Z;

R₇″

is H, NR₈R₈′

or OR₈; and

R₄′

, R₅, R₅′

, R₆, R₇′

, R₈, and R₈′

are each independently H or C₁-C₆ alkyl.

25. The method of claim 13, wherein R₄ and R₄′

are each ethyl.

26. The method of claim 13, wherein the dual acting SNRI-NMDA antagonist is a single enantiomer.

27. The method of claim 1, wherein the dual acting SNRI-NMDA antagonist is represented by the following structural formula:

28. The method of claim 1, wherein the dual acting SNRI-NMDA antagonist is a compound of Formula III:

29. The method of claim 28, wherein:

Ar are each independently selected from the group consisting of phenyl, phenoxy, benzyl, naphthyl, thiofuranyl, tetrahydronaphthyl, pyridyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, cyclohexyl, cycloheptyl and cyclopentyl, optionally Ar is substituted with one or more amino, alkylamino, dialkylamino, alkyl, hydroxyl, alkoxy, mercapto, alkylthio, alkylsulfinyl, acyl, halogen, perhaloalkyl, trifluoromethyl, trifluoromethylthio, trifluoromethylsulfonyl, and/or trifluoromethoxy;

optionally each Ar is taken together to form a fused polycyclic ring system selected from the group consisting of dibenzo[7]annulene, a dihydrodibenzo[7]annulene, a xanthenyl and a thioxanthenyl;

R₁ is selected from the group consisting of H and alkyl;

R₂ and R₂′

are each independently selected from the group consisting of H and alkyl;

A is a liner or branched alkylene or alkenylene, optionally interrupted with an —

O—

; and

optionally R₂ and/or R₂′

are taken together with A to form a heterocycle.

30. The method of claim 28, wherein the dual acting SNRI-NMDA antagonist is a single enantiomer.

31. The method of claim 1, wherein the dual acting SNRI-NMDA antagonist is at least one member selected from the group consisting of compounds represented by the following structural formulas:

32. The method of claim 1, wherein the genitourinary disorder is associated with control of the smooth muscle of the urinary bladder.

33. The method of claim 1, wherein the genitourinary disorder is at least one disorder selected from the group consisting of overactive bladder, overactive bladder with sphincter dysfunction, urinary incontinence, urge urinary incontinence, stress urinary incontinence, Fowler'"'"'s Syndrome, outlet obstruction, outlet insufficiency, pelvic hypersensitivity, sphincteric spasticity, detrusor hyperreflexia (neurogenic bladder), detrusor instability, benign prostatic hyperplasia (BPH), urethral stricture disease, tumors, interstitial (cell) cystitis, chronic pelvic pain syndrome, prostatodynia, prostatis, vulvodynia, vulvar vestibulitis, urethritis, and orchidalgia.

34. The method of claim 1, wherein the genitourinary disorder is characterized by bladder-sphincter dyssynergia.

35. The method of claim 1, wherein the genitourinary disorder is a genitourinary disorder with outlet obstruction.

36. The method of claim 1, wherein the genitourinary disorder is at least one disorder selected from the group consisting of dry overactive bladder, overactive bladder with sphincter dysfunction, urge urinary incontinence, Fowler'"'"'s Syndrome, chronic pelvic pain syndrome, prostatitis, prostatodynia, vulvodynia, vestibulitis, and benign prostatic hyperplasia.

37. The method of claim 1, wherein the genitourinary disorder is urge urinary incontinence.

38. The method of claim 1, wherein the subject is a human.

39. The method of claim 1, wherein the subject does not have a chemical dependency.

40. The method of claim 1, wherein the dual acting SNRI-NMDA antagonist is administered on an as-needed basis.

41. The method of claim 40, wherein the dual acting SNRI-NMDA antagonist is administered prior to commencement of an activity wherein suppression of a genitourinary disorder is desired.

42. The method of claim 40, wherein the dual acting SNRI-NMDA antagonist is administered from about 0 minutes to about 10 hours prior to commencement of an activity wherein suppression of a genitourinary disorder is desired.

43. The method of claim 40, wherein the dual acting SNRI-NMDA antagonist is administered from about 0 minutes to about 3 hours prior to commencement of an activity wherein suppression of a genitourinary disorder is desired.

44. The method of claim 1, wherein the dual acting SNRI-NMDA antagonist is administered in a controlled release formulation.

45. The method of claim 44, wherein the dual acting SNRI-NMDA antagonist is administered in a delayed release formulation.

46. The method of claim 44, wherein the dual acting SNRI-NMDA antagonist is administered in a pulsatile release formulation.

47. The method of claim 44, wherein the dual acting SNRI-NMDA antagonist is administered in a sustained release formulation.

48. The method of claim 1, wherein the dual acting SNRI-NMDA antagonist is administered orally.

49. The method of claim 37, wherein the dual acting SNRI-NMDA antagonist is administered in at least one dosage form selected from the group consisting of:

a tablet, a capsule, a caplet, a pill, a gel cap, a troche, a lozenge, a magma, a dispersion, a solution, a suspension, a syrup, a granule, a bead, a powder and a pellet.

50. The method of claim 49, wherein the dosage form is a tablet.

51. The method of claim 49, wherein the dosage form is a capsule.

52. The method of claim 1, wherein the dual acting SNRI-NMDA antagonist is administered transmucosally.

53. The method of claim 52, wherein the dual acting SNRI-NMDA antagonist is administered sublingually.

54. The method of claim 52, wherein the dual acting SNRI-NMDA antagonist is administered bucally.

55. The method of claim 52, wherein the dual acting SNRI-NMDA antagonist is administered transurethrally.

56. The method of claim 52, wherein the dual acting SNRI-NMDA antagonist is administered rectally.

57. The method of claim 1, wherein the dual acting SNRI-NMDA antagonist is administered by inhalation.

58. The method of claim 1, wherein the dual acting SNRI-NMDA antagonist is administered intravesically.

59. The method of claim 1, wherein the dual acting SNRI-NMDA antagonist is administered topically.

60. The method of claim 1, wherein the dual acting SNRI-NMDA antagonist is administered transdermally.

61. The method of claim 1, wherein the dual acting SNRI-NMDA antagonist is administered parenterally.

62. The method of claim 1, wherein the heart rate of the subject is not increased by more than 50%.

63. The method of claim 1, wherein the heart rate of the subject is not increased by more than 25%.

64. The method of claim 1, wherein the heart rate of the subject is not increased by more than 10%.

65. The method of claim 1, wherein the arterial pressure of the subject is not increased by more than 25%.

66. The method of claim 1, wherein the arterial pressure of the subject is not increased by more than 10%.

67. The method of claim 1, further comprising administering to the subject a therapeutically effective amount of at least one additional agent selected from the group consisting of an antimuscarinic, oxybutynin, DITROPAN®

, tolterodine, flavoxate, propiverine, trospium, a muscosal surface protectant, ELMIRON®

, an antihistamine, hydroxyzine hydrochloride, pamoate, an anticonvulsant, NEURONTIN®

, KLONOPIN®

, a muscle relaxant, VALIUM®

, a bladder antispasmodic, URIMAX®

, a tricyclic antidepressant, imipramine, a nitric oxide donor, nitroprusside, a β

₃-adrenergic receptor agonist, a bradykinin receptor antagonist, a neurokinin receptor antagonist, a sodium channel modulator, such as TTX-R sodium channel modulator and/or activity dependent sodium channel modulator and a Cav2.2 subunit calcium channel modulator.

68. A method of treating a genitourinary disorder in a subject in need of treatment, comprising administering to a subject in need of treatment a therapeutically effective amount of at least one dual acting SNRI-NMDA antagonist selected from the group consisting of compounds with the following structural formulas:

69. The method of claim 68, wherein the dual acting SNRI-NMDA antagonist is represented by the following structural formula:

70. The method of claim 69, wherein the dual acting SNRI-NMDA antagonist is administered in a dose of 200 mg.

71. The method of claim 69, wherein the dual acting SNRI-NMDA antagonist is administered in a dose of 400 mg.

72. The method of claim 69, wherein the dual acting SNRI-NMDA antagonist is administered in a dose of 600 mg.

73. The method of claim 68, wherein the dual acting SNRI-NMDA antagonist is represented by the following structural formula:

74. The method of claim 73, wherein the dual acting SNRI-NMDA antagonist is administered in a dose of between 30 mg and 200 mg.

75. The method of claim 68, wherein the genitourinary disorder is associated with control of the smooth muscle of the urinary bladder.

76. The method of claim 68, wherein the genitourinary disorder is at least one disorder selected from the group consisting of overactive bladder, overactive bladder with sphincter dysfunction, urinary incontinence, urge urinary incontinence, stress urinary incontinence, Fowler'"'"'s Syndrome, outlet obstruction, outlet insufficiency, pelvic hypersensitivity, sphincteric spasticity, detrusor hyperreflexia (neurogenic bladder), detrusor instability, benign prostatic hyperplasia (BPH), urethral stricture disease, tumors, interstitial (cell) cystitis, chronic pelvic pain syndrome, prostatodynia, prostatis, vulvodynia, vulvar vestibulitis, urethritis, and orchidalgia.

77. The method of claim 68, wherein the genitourinary disorder is characterized by bladder-sphincter dyssynergia.

78. The method of claim 68, wherein the genitourinary disorder is a genitourinary disorder with outlet obstruction.

79. The method of claim 68, wherein the genitourinary disorder is at least one disorder selected from the group consisting of dry overactive bladder, overactive bladder with sphincter dysfunction, urge urinary incontinence, Fowler'"'"'s Syndrome, chronic pelvic pain syndrome, prostatitis, prostatodynia, vulvodynia, vestibulitis, and benign prostatic hyperplasia.

80. The method of claim 68, wherein the genitourinary disorder is urge urinary incontinence.

81. The method of claim 68, wherein the subject is a human.

82. The method of claim 68, wherein the subject does not have a chemical dependency.

83. A method of treating overactive bladder in a subject comprising administering to the subject a therapeutically effective amount of a dual acting SNRI-NMDA antagonist, such that the overactive bladder is treated.

84-87. -87. (canceled)

88. A method of treating overactive bladder in a subject in need of treatment, comprising administering to said subject a therapeutically effective amount of at least one dual acting SNRI-NMDA antagonist selected from the group consisting of compounds with the following structural formulas:

89-90. -90. (canceled)

91. A kit for treating a genitourinary disorder in a subject in need of treatment, comprising:

a dual acting SNRI-NMDA antagonist, packaged with an instructional insert for using the dual acting SNRI-NMDA antagonist for the treatment of the genitourinary disorder.

92-94. -94. (canceled)

95. A kit for treating a genitourinary disorder in a subject in need of treatment, comprising:

an SNRI packaged with an instructional insert for using the SNRI together with an NMDA antagonist for the treatment of a genitourinary disorder.

96. (canceled)

97. A kit for treating a genitourinary disorder in a subject in need of treatment, comprising:

an NMDA antagonist packaged with an instructional insert for using the NMDA antagonist together with an SNRI for the treatment of a genitourinary disorder.

98-107. -107. (canceled)